ALK-Abello A/S - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
45 Pages - GMD12074


Global Markets Direct’s, ‘ALK-Abello A/S - Product Pipeline Review - 2014’, provides an overview of the ALK-Abello A/S’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ALK-Abello A/S’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of ALK-Abello A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ALK-Abello A/S’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ALK-Abello A/S’s pipeline products

Reasons to buy

- Evaluate ALK-Abello A/S’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ALK-Abello A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ALK-Abello A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ALK-Abello A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ALK-Abello A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ALK-Abello A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ALK-Abello A/S Snapshot 5
ALK-Abello A/S Overview 5
Key Information 5
Key Facts 5
ALK-Abello A/S - Research and Development Overview 6
Key Therapeutic Areas 6
ALK-Abello A/S - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
ALK-Abello A/S - Pipeline Products Glance 11
ALK-Abello A/S - Late Stage Pipeline Products 11
Pre-Registration Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
ALK-Abello A/S - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
ALK-Abello A/S - Early Stage Pipeline Products 14
Discovery Products/Combination Treatment Modalities 14
ALK-Abello A/S - Drug Profiles 15
allergenic pollen extract of timothy 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
short ragweed pollen allergen OD 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
MK-7243 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MK-8237 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
AVANZ Olive Immunotherapy for Allergic Rhinitis 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Avanz Phleum Pratense 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ALK Birch Pollen Vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ALK Next Generation Vaccine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ALK Recombinant Cat Vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ALK-Abello A/S - Pipeline Analysis 29
ALK-Abello A/S - Pipeline Products by Route of Administration 29
ALK-Abello A/S - Pipeline Products by Molecule Type 30
ALK-Abello A/S - Recent Pipeline Updates 31
ALK-Abello A/S - Dormant Projects 37
ALK-Abello A/S - Company Statement 38
ALK-Abello A/S - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
ALK-Abello A/S - Key Manufacturing Facilities 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
ALK-Abello A/S, Key Information 5
ALK-Abello A/S, Key Facts 5
ALK-Abello A/S - Pipeline by Indication, 2014 8
ALK-Abello A/S - Pipeline by Stage of Development, 2014 9
ALK-Abello A/S - Monotherapy Products in Pipeline, 2014 10
ALK-Abello A/S - Pre-Registration, 2014 11
ALK-Abello A/S - Phase III, 2014 12
ALK-Abello A/S - Phase II, 2014 13
ALK-Abello A/S - Discovery, 2014 14
ALK-Abello A/S - Pipeline by Route of Administration, 2014 29
ALK-Abello A/S - Pipeline by Molecule Type, 2014 30
ALK-Abello A/S - Recent Pipeline Updates, 2014 31
ALK-Abello A/S - Dormant Developmental Projects,2014 37
ALK-Abello A/S, Other Locations 41
ALK-Abello A/S, Subsidiaries 41
ALK-Abello A/S, Key Manufacturing Facilities 43

List of Figures
ALK-Abello A/S - Pipeline by Top 10 Indication, 2014 7
ALK-Abello A/S - Pipeline by Stage of Development, 2014 9
ALK-Abello A/S - Monotherapy Products in Pipeline, 2014 10
ALK-Abello A/S - Pipeline by Top 10 Route of Administration, 2014 29
ALK-Abello A/S - Pipeline by Top 10 Molecule Type, 2014 30


Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.
+1 212 564 2838
+1 212 564 8133 fax